Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its cardiac gene therapy programs and optimized AAV manufacturing approach will be presented at the 29 th  Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 11-15, 2026 in Boston, MA. “We're excited to return to ASGCT with a broad and compelling set of presentations that highlight the depth of Lexeo's science and continued progress across our pipeline, from encouraging cardiac and neurologic data in Friedreich ataxia (FA) to a novel TNNI3 gene therapy program enabled by an innovative and clinically relevant porcine disease model, and an industry-leading, highly optimized AAV manufacturing platform,” said Narinder Bhalla, MD, Chief Medical Officer of Lexeo Therapeutics.